The Journal of Experimental Medicine
ELISpot, FluoroSpot and ELISA kits from Mabtech
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
Published 20 September 2004. doi:10.1084/jem.20041270
Rockefeller University Press, 0022-1007 $8.00
JEM, Volume 200, Number 6, 701-712
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 1165K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lichterfeld, M.
Right arrow Articles by Altfeld, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lichterfeld, M.
Right arrow Articles by Altfeld, M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Loss of HIV-1–specific CD8+ T Cell Proliferation after Acute HIV-1 Infection and Restoration by Vaccine-induced HIV-1–specific CD4+ T Cells

Mathias Lichterfeld1, Daniel E. Kaufmann1, Xu G. Yu1, Stanley K. Mui1, Marylyn M. Addo1, Mary N. Johnston1, Daniel Cohen2, Gregory K. Robbins1, Eunice Pae2, Galit Alter1, Alysse Wurcel1,3, David Stone3, Eric S. Rosenberg1, Bruce D. Walker1,4, and Marcus Altfeld1

1 Partners AIDS Research Center, Massachusetts General Hospital and Division of AIDS, Harvard Medical School, Boston, MA 02129
2 Fenway Community Health Care Center, Boston, MA 02115
3 Lemuel Shattuck Hospital, Boston, MA 02130
4 Howard Hughes Medical Institute, Chevy Chase, MD 20815

Address correspondence to Marcus Altfeld, Partners AIDS Research Center, Massachusetts General Hospital, 149 13th St., Boston, MA 02129. Phone: (617) 724-2461; Fax: (617) 724-8586; email: maltfeld{at}partners.org

Virus-specific CD8+ T cells are associated with declining viremia in acute human immunodeficiency virus (HIV)1 infection, but do not correlate with control of viremia in chronic infection, suggesting a progressive functional defect not measured by interferon {gamma} assays presently used. Here, we demonstrate that HIV-1–specific CD8+ T cells proliferate rapidly upon encounter with cognate antigen in acute infection, but lose this capacity with ongoing viral replication. This functional defect can be induced in vitro by depletion of CD4+ T cells or addition of interleukin 2–neutralizing antibodies, and can be corrected in chronic infection in vitro by addition of autologous CD4+ T cells isolated during acute infection and in vivo by vaccine-mediated induction of HIV-1–specific CD4+ T helper cell responses. These data demonstrate a loss of HIV-1–specific CD8+ T cell function that not only correlates with progressive infection, but also can be restored in chronic infection by augmentation of HIV-1–specific T helper cell function. This identification of a reversible defect in cell-mediated immunity in chronic HIV-1 infection has important implications for immunotherapeutic interventions.

Key Words: HIV-1 • CD8+ T cells • CD4+ T cells • vaccine • protective immunity

Abbreviations used in this paper: CFSE, carboxyfluorescein succinimidyl ester; FSC, forward scatter; SFC, spot-forming cell; SSC, side scatter.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS